At the 61st ASH Annual Meeting & Exposition, Sabina Chiaretti, “Sapienza” University of Rome, discusses her presentation: Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. A Single Center Experience.
1. What are the limitations of current therapeutic options for patients with relapsed/refractory acute lymphoblastic leukemia (ALL)? (0:05)
2. What is the mechanism of action of blinatumomab? (0:54)
3. What were the major findings of your retrospective study? (1:46)
4. What did the study findings teach us about the safety profile of blinatumomab and how to manage toxicities? (2:58)
5. How are these findings likely to impact on clinical practice? (4:43)
Sabina Chiaretti has received consultancy fees from Amgen, Shire, Pfizer and incyte.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Leukaemia
PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Jorge Cortes, EHA 2022: Magrolimab plus azacitidine in the patients with AML and HR MDS
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!